All In Biotech

Drug Trial Radar · NCT05718921

A Safety, Tolerability and Pharmacokinetics Study of Topical Ointment YR001 in Adult Healthy Volunteers

A Randomized, Double-blind, Placebo-controlled Single and Multiple Dose Phase I Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics of Topical Ointment YR001 in Adult Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: Jan 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

54

Actual

Start

Apr 8, 2023

Primary completion

Aug 14, 2023

Study completion Dec 14, 2023

Sponsor

Sponsor type
Industry
First posted
Feb 8, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is to evaluate the safety, tolerability, and pharmacokinetics of YR001 topical ointment in healthy adult subjects.

Conditions

  • Atopic Dermatitis
  • Psoriasis

Interventions

  • YR001 Dose A on low body surface areaDrug

    Part A: Single topical dose

  • YR001 Dose A on middle body surface areaDrug

    Part A: Single topical dose

  • YR001 Dose A on high body surface areaDrug

    Part A: Single topical dose

  • YR001 Dose B on low body surface areaDrug

    Part A: Single topical dose

  • YR001 Dose B on middle body surface areaDrug

    Part A: Single topical dose

  • YR001 Dose B on high body surface areaDrug

    Part A: Single topical dose

  • Placebo on low body surface areaDrug

    Part A: Single topical dose

  • Placebo on middle body surface areaDrug

    Part A: Single topical dose

  • Placebo on high body surface areaDrug

    Part A: Single topical dose

  • YR001 Dose A on high body surface area twice dailyDrug

    Part B: Multiple topical dose

  • YR001 Dose B on high body surface area twice dailyDrug

    Part B: Multiple topical dose

  • Placebo on high body surface area twice dailyDrug

    Part B: Multiple topical dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Safety and Maximum Tolerate Dose (MTD)Time frame: day 0 to day 8
  2. Part B: Safety and Maximum Tolerate Dose (MTD)Time frame: day 0 to day 22

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • California Dermatology & Clinical Research Institute

    Encinitas, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.